MK-0767

DB12055InvestigationalSmall molecule

MK0767 has been used in trials studying the treatment of Dyslipidemia, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type II, among others.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor alpha and Peroxisome proliferator-activated receptor gamma
Curator reviewed
Formula / weight: C₂₀H₁₇F₃N₂O₅ · 422.36 g/mol (avg)
Code names: MK 0767

Resolves to

Compound

UNIIY180U02GSBCAS934017-32-0PubChem56842109

Structure

InChIKeyORZMUVMQJPGFOM-UHFFFAOYSA-NSMILESCOC1=CC=C(CC2OC(=O)NC2=O)C=C1C(=O)NCC1=CC=C(C=C1)C(F)(F)F

Targets

Q07869PPARAP37231PPARG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-0767, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account